Epidermal growth factor receptor classical activating mutants (EGFR classical mutants)

Epidermal growth factor receptor (EGFR) classical activating mutants primarily refer to deletions in exon 19 and the L858R point mutation in exon 21 of the EGFR gene [1]. These specific alterations lead to the constitutive, ligand-independent activation of the receptor's tyrosine kinase domain, which drives essential oncogenic pathways including PI3K/AKT and MAPK [2]. These mutations are the most frequent genomic drivers in non-small cell lung cancer (NSCLC), particularly among non-smokers and East Asian populations [3]. Therapeutic management involves the use of EGFR tyrosine kinase inhibitors (TKIs), which are designed to bind to the ATP-binding pocket of the mutated kinase to halt tumor progression [4]. While first- and second-generation TKIs were the historical standard, third-generation inhibitors like osimertinib are now preferred due to their superior efficacy and ability to target the T790M resistance mutation while sparing wild-type EGFR [5][6]. Despite high initial response rates, patients eventually develop resistance through secondary mutations or bypass signaling pathways, necessitating ongoing monitoring via tissue or liquid biopsies [4][6].

Other names

EGFR sensitizing mutationsEGFR common mutationsEGFR Exon 19 deletionEGFR L858R mutationEGFR kinase domain mutations

Inhibition of the intracellular tyrosine kinase domain by competing with adenosine triphosphate (ATP) for binding, thereby blocking downstream oncogenic signaling pathways such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR.